Evidence map›Paper›PMID 25373319›Full record

ArticleBMC cancer2014

Effects of insulin on human pancreatic cancer progression modeled in vitro.

Michelle T Chan, Gareth E Lim, Søs Skovsø, Yu Hsuan Carol Yang, Tobias Albrecht, Emilyn U Alejandro, Corinne A Hoesli, James M Piret, Garth L Warnock, James D Johnson

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Changes in Cells Associated with Insulin Resistance.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Pancreatic Cancer and Diabetes Mellitus.Current treatment options in gastroenterology · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Michelle T Chan
Gareth E Lim
Søs Skovsø
Yu Hsuan Carol Yang
Tobias Albrecht
Emilyn U Alejandro
Corinne A Hoesli
James M Piret
Garth L Warnock
James D JohnsonDepartment of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada. James.D.Johnson@ubc.ca.
University of British Columbia · CA

Funding

Mechanisms of Developmental Programing of beta-cell Susceptibility to GlucolipotoxicityK01DK103823 · NIDDK · UNIVERSITY OF MINNESOTA · PI ALEJANDRO, EMILYN · 2014 to 2017
$572k
NIDDK NIH HHS K01 DK103823
6 · The paper itself

Abstract

backgroundPancreatic adenocarcinoma is one of the most lethal cancers, yet it remains understudied and poorly understood. Hyperinsulinemia has been reported to be a risk factor of pancreatic cancer, and the rapid rise of hyperinsulinemia associated with obesity and type 2 diabetes foreshadows a rise in cancer incidence. However, the actions of insulin at the various stages of pancreatic cancer progression remain poorly defined.

methodsHere, we examined the effects of a range of insulin doses on signalling, proliferation and survival in three human cell models meant to represent three stages in pancreatic cancer progression: primary pancreatic duct cells, the HPDE immortalized pancreatic ductal cell line, and the PANC1 metastatic pancreatic cancer cell line. Cells were treated with a range of insulin doses, and their proliferation/viability were tracked via live cell imaging and XTT assays. Signal transduction was assessed through the AKT and ERK signalling pathways via immunoblotting. Inhibitors of AKT and ERK signalling were used to determine the relative contribution of these pathways to the survival of each cell model.

resultsWhile all three cell types responded to insulin, as indicated by phosphorylation of AKT and ERK, we found that there were stark differences in insulin-dependent proliferation, cell viability and cell survival among the cell types. High concentrations of insulin increased PANC1 and HPDE cell number, but did not alter primary duct cell proliferation in vitro. Cell survival was enhanced by insulin in both primary duct cells and HPDE cells. Moreover, we found that primary cells were more dependent on AKT signalling, while HPDE cells and PANC1 cells were more dependent on RAF/ERK signalling.

conclusionsOur data suggest that excessive insulin signalling may contribute to proliferation and survival in human immortalized pancreatic ductal cells and metastatic pancreatic cancer cells, but not in normal adult human pancreatic ductal cells. These data suggest that signalling pathways involved in cell survival may be rewired during pancreatic cancer progression.

Indexed as

BenzylaminesCarcinoma, Pancreatic DuctalCell Line, TumorCell ProliferationCell SurvivalCell Transformation, NeoplasticDisease ProgressionExtracellular Signal-Regulated MAP KinasesHumansIndolesInsulinMAP Kinase Signaling SystemModels, BiologicalPancreatic DuctsPancreatic NeoplasmsPhenols5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinoneAkt-I-1,2 compoundBenzylaminesExtracellular Signal-Regulated MAP KinasesIndolesInsulinPhenolsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-rafQuinoxalines

Identifiers

PMID25373319
PMCPMC4233074
OpenAlexW1973765054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.